Theriva Biologics, Inc.: Theriva Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results

Realtime	Geld	Brief	Zeit
	0,385	0,400	28.04.
	0,387	0,398	26.04.

Realtime

Geld

Brief

Zeit

0,385

0,400

28.04.

0,387

0,398

26.04.

Theriva Biologics, Inc.: Theriva Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results

ROCKVILLE, Md., March 19, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that it plans to host a conference call on Monday, March 25, 2024, at 8:30 a.m. ET to discuss its financial results for the full year ended December 31, 2023 and provide a corporate update.

Individuals may participate in the live call via telephone by dialing 1-877-451-6152, under "Events" or by clicking here, up to 90 days after the call.

About Theriva Biologics, Inc.

Theriva Biologics.

For further information, please contact:
Investor Relations:
Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
917-680-5608
Source: Theriva Biologics, Inc.

Großer Insider-Report 2024 von Dr. Dennis Riedl

Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.

Hier klicken

Zeit	Aktuelle Nachrichten
Do	Theriva Biologics, Inc.: Theriva Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinic	ROCKVILLE, Md., April 25, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases... ► Artikel lesen
Di	Theriva Biologics Announces Positive Data From Phase 1 Trial Of VCN-01 In Intraocular Retinoblastoma
Di	Theriva Biologics, Inc.: Theriva Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma	-Phase 1 trial in collaboration with Sant Joan de Déu-Barcelona Children's Hospital (SJD) determined to have a positive outcome by the study Monitoring Committee- -Safety and clinical outcomes support... ► Artikel lesen
Di	Theriva Biologics, Inc. - 8-K, Current Report
22.04.	Theriva Biologics, Inc.: Theriva Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting	- Lead product candidate, VCN-01 in combination with liposomal irinotecan demonstrated enhanced anti-tumor effects in a human pancreatic mouse xenograft- - The observed synergy emphasizes VCN-01's... ► Artikel lesen

Zeit

Aktuelle Nachrichten

Theriva Biologics, Inc.: Theriva Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinic

ROCKVILLE, Md., April 25, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases...
► Artikel lesen

Theriva Biologics Announces Positive Data From Phase 1 Trial Of VCN-01 In Intraocular Retinoblastoma

Theriva Biologics, Inc.: Theriva Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma

-Phase 1 trial in collaboration with Sant Joan de Déu-Barcelona Children's Hospital (SJD) determined to have a positive outcome by the study Monitoring Committee- -Safety and clinical outcomes support...
► Artikel lesen

Theriva Biologics, Inc. - 8-K, Current Report

22.04.

Theriva Biologics, Inc.: Theriva Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting

- Lead product candidate, VCN-01 in combination with liposomal irinotecan demonstrated enhanced anti-tumor effects in a human pancreatic mouse xenograft- - The observed synergy emphasizes VCN-01's...
► Artikel lesen

	Indizes	Kurs	%	News 24 h / 7 T	Aufrufe 7 Tage


	Aktien	Kurs	%	News 24 h / 7 T	Aufrufe 7 Tage


	Xetra-Orderbuch


	Fonds	Kurs	%


	Devisen	Kurs	%


	Rohstoffe	Kurs	%


	Themen	Kurs	%



Erweiterte Suche

THERIVA BIOLOGICS INC

Theriva Biologics, Inc.: Theriva Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results